المنشورات طباعة Xie Z, Fernandez J, Lasho TL, Finke CM, Amundson M, McCullough K, LaPlant B, Mangaonkar AA, Gangat N, Reichard KK, Elliott MA, Witzig TE, Patnaik MM. High-dose IV ascorbic acid therapy in CCUS patients with TET2 mutations. Blood. 2024 Oct 1 Epub 2024 Oct 01 View PubMed Steinauer N, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar AA, Saliba AN, Torghabeh M, Litzow MR, Hogan WJ, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Yi CA, Tefferi A, Gangat N. Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent. Haematologica 2024 Aug 1; 109 (8):2706-2710 Epub 2024 Aug 01 View PubMed Li M, Baranwal A, Gurney M, Shah SN, Al-Kali A, Alkhateeb H, Foran J, Arana Yi C, Ongie L, Chen D, Mangaonkar A, McCullough K, Tefferi A, Lasho T, Finke C, Patnaik MM, Shah MV. The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance. Blood Adv. 2024 Jun 25; 8 (12):3130-3139 View PubMed Johnson IM, Karrar O, Rana M, Iftikhar M, Chen S, McCullough K, Saliba AN, Al-Kali A, Alkhateeb H, Begna K, Litzow M, Hogan WJ, Shah M, Patnaik MM, Pardanani A, Hermann J, Tefferi A, Gangat N. Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents. Br J Haematol. 2024 Apr; 204 (4):1232-1237 Epub 2024 Feb 04 View PubMed Kuhn AK, Martin C, Galardy P, McCullough K, Greenmyer J, O'Keefe M, Walter A, Thompson C, Ferdjallah A, Kalmes J, Kohorst M. Attempted desensitization to calaspargase pegol: a familiar approach to a new problem. Leuk Lymphoma. 2024 Mar; 65 (3):407-409 Epub 2023 Nov 22 View PubMed Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, Abdallah M, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Tefferi A. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2024 Feb; 99 (2):193-202 Epub 2023 Dec 10 View PubMed Gangat N, McCullough K, Abdelmagid M, Karrar O, Powell M, Al-Kali A, Alkhateeb H, Begna K, Mangaonkar A, Saliba A, Torghabeh MH, Litzow M, Hogan W, Shah M, Patnaik M, Pardanani A, Badar T, Foran J, Palmer J, Sproat L, Yi CA, Tefferi A. Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia. Haematologica 2024 Jan 1; 109 (1):187-292 Epub 2024 Jan 01 View PubMed Tefferi A, Pardanani A, Al-Kali A, Alkhateeb H, McCullough K, Patnaik M, Hogan WJ, Begna K, Elliott MA, Khera N, Palmer JM, Gangat N, Kelemen K, Orazi A, Chen D, Reichard KK. Mast cell cytomorphology and treatment outcome in mast cell leukemia. Am J Hematol 2024 Jan; 99 (1):E5-E8 Epub 2023 Sept 21 View PubMed McCullough KB. Do You See Me? J Clin Oncol. 2023 Dec 10; 41 (35):5473-5474 Epub 2023 Oct 24 View PubMed Gangat N, Ilyas R, Johnson IM, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Tefferi A. Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy. Haematologica 2023 Nov 1; 108 (11):3170-3174 Epub 2023 Nov 01 View PubMed Pritzl SL, Gurney M, Badar T, Ferrer A, Lasho T, Finke C, Mangaonkar A, McCullough K, Gangat N, Fernandez J, Al-Kali A, Viswanatha D, He R, Foran J, Patnaik MM. Clinical and molecular spectrum and prognostic outcomes of U2AF1 mutant clonal hematopoiesis- a prospective mayo clinic cohort study. Leuk Res. 2023 Feb; 125:107007 Epub 2022 Dec 28 View PubMed McCullough KB. Do you see me?. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2023; 41 (35):5473-4 Gangat N, Johnson I, McCullough K, Farrukh F, Al-Kali A, Alkhateeb H, Begna K, Mangaonkar A, Litzow M, Hogan W, Shah M, Patnaik M, Pardanani A, Tefferi A. Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naive acute myeloid leukemia. Haematologica. 2022 Oct 1; 107 (10):2501-2505 Epub 2022 Oct 01 View PubMed Johnson IM, Bezerra ED, Farrukh F, McCullough K, Al-Kali A, Alkhateeb HB, Begna K, Litzow MR, Hogan WJ, Shah MV, Patnaik MM, Tefferi A, Gangat N. Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents. Blood Adv. 2022 Sep 13; 6 (17):5227-5231 View PubMed Golbach AP, McCullough KB, Soefje SA, Mara KC, Shanafelt TD, Merten JA. Evaluation of Burnout in a National Sample of Hematology-Oncology Pharmacists. JCO Oncol Pract. 2022 Aug; 18 (8):e1278-e1288 Epub 2021 Nov 18 View PubMed Shah MV, Mangaonkar AA, Begna KH, Alkhateeb HB, Greipp P, Nanaa A, Elliott MA, Hogan WJ, Litzow MR, McCullough K, Tefferi A, Gangat N, Patnaik MM, Al-Kali A, He R, Chen D. Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms. Blood Cancer J. 2022 Jul 8; 12 (7):106 Epub 2022 July 08 View PubMed Farrukh F, Chetram D, Al-Kali A, Foran J, Patnaik M, Badar T, Begna K, Hook C, Hogan W, McCullough KB, Mangaonkar A, He R, Gangat N, Tefferi A. Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts. Am J Hematol 2022 Jun 1; 97 (6):E210-E214 Epub 2022 Mar 29 View PubMed Dalvin LA, Olsen TW, Bakri SJ, McCullough K, Tefferi A, Al-Kali A. Busulfan Treatment for Myeloproliferative Disease may Reduce Injection Burden in Vascular Endothelial Growth Factor-Driven Retinopathy. Am J Ophthalmol Case Rep. 2022 Jun; 26:101554 Epub 2022 Apr 21 View PubMed Mangaonkar AA, Lasho TL, Finke C, Ketterling RP, Reichard KK, McCullough K, Gangat N, Al-Kali A, Begna KH, Hogan WH, Litzow MR, Alkhateeb H, Shah M, Pardanani A, Tefferi A, Al Ali NH, Talati C, Sallman D, Padron E, Komrokji R, Patnaik MM. SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity. Haematologica. 2022 May 1; 107 (5):1189-1192 Epub 2022 May 01 View PubMed Thanarajasingam G, Minasian LM, Bhatnagar V, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gormley N, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Kwong YL, Little RF, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Nair A, Nastoupil L, Robertson K, Sidana S, Smedby KE, Sonneveld P, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Seymour JF, Habermann TM. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2022 May; 9 (5):e374-e384 View PubMed Herrmann J, McCullough KB, Habermann TM. How I treat cardiovascular complications in patients with lymphoid malignancies. Blood. 2022 Mar 10; 139 (10):1501-1516 View PubMed Vaxman I, Abeykoon J, Dispenzieri A, Kumar SK, Buadi F, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Reeder C, Sher T, Hayman S, Kourelis T, Warsame R, Muchtar E, Leung N, Go R, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Kristen M, Kapoor P, Gertz MA. "Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience. Blood Cancer J. 2021 Dec 7; 11 (12):196 Epub 2021 Dec 07 View PubMed McCullough KB, Kuhn AK, Patnaik MM. Treatment advances for pediatric and adult onset neoplasms with monocytosis. Curr Hematol Malig Rep. 2021 Jun; 16 (3):256-266 Epub 2021 Mar 16 View PubMed May HP, Barreto EF, Mara KC, McCullough KB, Patnaik MS, Leung N, Habermann TM. Risk for Significant Kidney Function Decline After Acute Kidney Injury in Adults With Hematologic Malignancy. Kidney Int Rep. 2021 Apr; 6 (4):1050-1057 Epub 2021 Jan 28 View PubMed Joshi M, Cook J, McCullough K, Nanaa A, Gangat N, Foran JM, Murthy HS, Kharfan-Dabaja MA, Sproat L, Palmer J, Pardanani A, Tefferi A, Begna K, Elliot M, Al-Kali A, Patnaik M, Shah MV, Hogan WJ, Litzow MR, Alkhateeb HB. Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. Blood Cancer J 2021 Mar 4; 11 (3):49 Epub 2021 Mar 04 View PubMed Habermann TM, Khurana A, Lentz R, Schmitz JJ, von Bormann AG, Young JR, Hunt CH, Christofferson SN, Nowakowski GS, McCullough KB, Horna P, Wood AJ, Macon WR, Kurtin PJ, Lester SC, Stafford SL, Chamarthy U, Khan F, Ansell SM, King RL. Analysis and impact of a multidisciplinary lymphoma virtual tumor board. Leuk Lymphoma. 2020 Dec; 61 (14):3351-3359 Epub 2020 Sept 23 View PubMed Morsia E, McCullough K, Joshi M, Cook J, Alkhateeb HB, Al-Kali A, Begna K, Elliott M, Hogan W, Litzow M, Shah M, Pardanani A, Patnaik M, Tefferi A, Gangat N. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. Am J Hematol. 2020 Dec; 95 (12):1511-1521 Epub 2020 Sept 16 View PubMed Ice LL, Bartoo GT, McCullough KB, Wolf RC, Dierkhising RA, Mara KC, Jowsey-Gregoire SG, Damlaj M, Litzow MR, Merten JA. A Prospective Survey of Outpatient Medication Adherence in Adult Allogeneic Hematopoietic Stem Cell Transplantation Patients. Biol Blood Marrow Transplant. 2020 Sep; 26 (9):1627-1634 Epub 2020 June 04 View PubMed McCullough KB, Patnaik MM. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes - Advances in treatment. Best Pract Res Clin Haematol. 2020 Jun; 33 (2):101130 Epub 2019 Dec 03 View PubMed Parikh SA, Achenbach SJ, Call TG, Rabe KG, Ding W, Leis JF, Kenderian SS, Chanan-Khan AA, Koehler AB, Schwager SM, Muchtar E, Fonder AL, McCullough KB, Nedved AN, Smith MD, Slager SL, Kay NE, Finnes HD, Shanafelt TD. The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. Cancer Med. 2020 May; 9 (10):3390-3399 Epub 2020 Mar 18 View PubMed Personett HA, Barreto EF, McCullough KB, Dierkhising R, Leung N, Habermann TM. Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma. Leuk Lymphoma. 2019 Sep; 60 (9):2271-2277 Epub 2019 June 21 View PubMed Formea CM, Nicholson WT, Vitek CR, Wix KK, McCullough KB, Cunningham JL, Zeuli JD, Matey ET, Merten JA, Richardson DM, Billings AL, Schramm GE. Implementation of a pharmacogenomics education program for pharmacists. Am J Health Syst Pharm. 2018 Dec 1; 75 (23):1939-1946 Epub 2018 Oct 09 View PubMed Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2018 Nov; 5 (11):e563-e598 Epub 2018 June 18 View PubMed McCullough KB, Hobbs MA, Abeykoon JP, Kapoor P. Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies. Curr Hematol Malig Rep. 2018 Apr; 13 (2):114-124 View PubMed Barreto JN, McCullough KB, Peskey CS, Dierkhising RA, Mara KC, Elliott MA, Gastineau DA, Al-Kali A, Gangat N, Letendre L, Hogan WJ, Litzow MR, Patnaik MM. Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy. Leuk Lymphoma. 2017 Nov; 58 (11):2588-2597 Epub 2017 May 09 View PubMed Yalniz FF, Hefazi M, McCullough K, Litzow MR, Hogan WJ, Wolf R, Alkhateeb H, Kansagra A, Damlaj M, Patnaik MM. Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017 Sep; 23 (9):1478-1484 Epub 2017 May 08 View PubMed Nanah R, McCullough K, Hogan W, Begna K, Patnaik M, Elliott M, Litzow M, Al-Kali A. Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience. Am J Hematol. 2017 Sep; 92 (9):866-871 Epub 2017 June 05 View PubMed Finnes HD, Chaffee KG, Call TG, Ding W, Kenderian SS, Bowen DA, Conte M, McCullough KB, Merten JA, Bartoo GT, Smith MD, Leis J, Chanan-Khan A, Schwager SM, Slager SL, Kay NE, Shanafelt TD, Parikh SA. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. Leuk Lymphoma. 2017 Jun; 58 (6):1376-1383 Epub 2016 Nov 08 View PubMed Barajas MR, McCullough KB, Merten JA, Dierkhising RA, Bartoo GT, Hashmi SK, Hogan WJ, Litzow MR, Patnaik MM, Wilson JW, Wolf RC, Wermers RA. Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole. Biol Blood Marrow Transplant. 2016 Mar; 22: (3)579-83. View PubMed McCullough KB, Patnaik MM. Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update. Curr Hematol Malig Rep. 2015 Sep; 10 (3):292-302 View PubMed Barreto JN, McCullough KB, Ice LL, Smith JA. Antineoplastic agents and the associated myelosuppressive effects: a review. J Pharm Pract. 2014 Oct; 27(5):440-6. Epub 2014 Aug 20. View PubMed Formea CM, Nicholson WT, McCullough KB, Berg KD, Berg ML, Cunningham JL, Merten JA, Ou NN, Stollings JL. Development and evaluation of a pharmacogenomics educational program for pharmacists. Am J Pharm Educ. 2013 Feb 12; 77 (1):10 View PubMed McCullough KB, Formea CM, Berg KD, Burzynski JA, Cunningham JL, Ou NN, Rudis MI, Stollings JL, Nicholson WT. Assessment of the pharmacogenomics educational needs of pharmacists. Am J Pharm Educ. 2011 Apr 11; 75 (3):51 View PubMed PST-20299192 الصفحة الرئيسية المنشورات